Studies in humans have shown the potential role of alterations in DNA methylation in the pathogenesis of Late-Onset Alzheimer's disease (LOAD). The epigenetic regulation of the genes involved in the Alzheimer's pathogenesis may help to explain the complexity of the LOAD. DNA was extracted from peripheral blood mononuclear cells of 100 Colombian AD patients (mean age 77.5± 5 years) and 100 healthy subjects (mean age 75.3± 5,5years). DNA was bisulfite treated using EZ DNA Methylation Direct Kit (Zymo-research). Primers were manually designed for the 5' region of the CpG Island in the APP promoter and APOE CpG Island on exon 4. The APP and APOE MS-HRMs were performed in a CFX 96 device (Bio-Rad), using 14 ng of bisulfite treated DNA. The quantitative results were obtained by interpolation of the first derived RFU normalized data, generated by the linear regression of the standard curve. The correlation coefficient of the linear regression of the standard curves was r2= 0.96 for APP gen and 0.898 for APOE gen The inter-assay and intra-assay reproducibilities were verified, having a coefficient of variance less than 0.5 between replicates. In a preliminary analysis we did not find differences in APP methylation levels between AD patients and control subjects (mean 2.14% +- 1.15 vs 2.05 +- 0.96). For APOE the difference was not significant in methylation levels (patients vs. Controls 73.01 vs 70.9) The present study tested changes in DNA methylation of in blood samples from Colombian LOAD patients, which showed no significant differences in comparison with control samples for APP and APOE genes. This is the first report of the analysis of APP and APOE DNA methylation levels in LOAD using the quantitative and cost-effective in Latin American AD patients. It would be important to analyze, in further studies, the methylation levels for additional candidate regions in several tissues from AD patients.